Focus on multiple myeloma

Cancer Cell

Volumn 6, Issue 5, 2004, Pages 439-444

  Mitsiades, Constantine S ^a   Mitsiades, Nicholas ^a,b   Munshi, Nikhil C ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; COLONY STIMULATING FACTOR 1; CYCLIN D1; CYCLIN D3; CYTOKINE; DEXAMETHASONE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 11; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MELPHALAN; OSTEOCLAST DIFFERENTIATION FACTOR; PREDNISONE; PROTEASOME INHIBITOR; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL FEATURE; CONSTIPATION; CYTOGENETICS; DRUG MEGADOSE; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; KARYOTYPE; MULTIPLE MYELOMA; NEUROPATHY; NONHUMAN; ONCOGENE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SOMNOLENCE;

EID: 7944221970     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.10.020     Document Type: Review

References (64)

1. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., Porter D., Hu M., Chin L., Richardson A., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 6:2004;17-32
2. Ashcroft A.J., Davies F.E., Morgan G.J. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol. 4:2003;284-292
3. Attal M., Harousseau J.L., Facon T., Guilhot F., Doyen C., Fuzibet J.G., Monconduit M., Hulin C., Caillot D., Bouabdallah R., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 349:2003;2495-2502
4. Avet-Loiseau H., Facon T., Grosbois B., Magrangeas F., Rapp M.J., Harousseau J.L., Minvielle S., Bataille R. Oncogenesis of multiple myeloma. 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation Blood. 99:2002;2185-2191
5. Berenson J.R., Hillner B.E., Kyle R.A., Anderson K., Lipton A., Yee G.C., Biermann J.S. American Society of Clinical Oncology clinical practice guidelines. The role of bisphosphonates in multiple myeloma J. Clin. Oncol. 20:2002;3719-3736
6. Bezieau S., Avet-Loiseau H., Moisan J.P., Bataille R. Activating Ras mutations in patients with plasma-cell disorders. A reappraisal Blood. 100:2002;1101-1102. author reply 1103
7. Body J.J., Greipp P., Coleman R.E., Facon T., Geurs F., Fermand J.P., Harousseau J.L., Lipton A., Mariette X., Williams C.D., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 97:2003;887-892
8. Bolick S.C., Landowski T.H., Boulware D., Oshiro M.M., Ohkanda J., Hamilton A.D., Sebti S.M., Dalton W.S. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia. 17:2003;451-457
9. Chauhan D., Uchiyama H., Akbarali Y., Urashima M., Yamamoto K., Libermann T.A., Anderson K.C. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood. 87:1996;1104-1112
10. Chesi M., Bergsagel P.L., Kuehl W.M. The enigma of ectopic expression of FGFR3 in multiple myeloma. A critical initiating event or just a target for mutational activation during tumor progression Curr. Opin. Hematol. 9:2002;288-293
11. Child J.A., Morgan G.J., Davies F.E., Owen R.G., Bell S.E., Hawkins K., Brown J., Drayson M.T., Selby P.J. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348:2003;1875-1883
12. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 91:1994;4082-4085
13. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., Lin B., Podar K., Gupta D., Chauhan D., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 98:2001;210-216
14. Davies F.E., Dring A.M., Li C., Rawstron A.C., Shammas M.A., O'Connor S.M., Fenton J.A., Hideshima T., Chauhan D., Tai I.T., et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 102:2003;4504-4511
15. Fonseca R., Barlogie B., Bataille R., Bastard C., Bergsagel P.L., Chesi M., Davies F.E., Drach J., Greipp P.R., Kirsch I.R., et al. Genetics and cytogenetics of multiple myeloma. A workshop report Cancer Res. 64:2004;1546-1558
16. Han J.H., Choi S.J., Kurihara N., Koide M., Oba Y., Roodman G.D. Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand. Blood. 97:2001;3349-3353
17. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479
18. Heslop, H.E., Stevenson, F.K., and Molldrem, J.J. (2003). Immunotherapy of hematologic malignancy. Hematology (Am. Soc. Hematol. Educ. Program) 2003, 331-349.
19. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.T., Treon S.P., Lin B., Schlossman R.L., Richardson P., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 96:2000;2943-2950
20. Hideshima T., Nakamura N., Chauhan D., Anderson K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 20:2001;5991-6000. a
21. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., Anderson K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:2001;3071-3076. b
22. Hideshima T., Bergsagel P.L., Kuehl W.M., Anderson K.C. Advances in biology of multiple myeloma. Clinical applications Blood. 104:2004;607-618
23. Hov H., Holt R.U., Ro T.B., Fagerli U.M., Hjorth-Hansen H., Baykov V., Christensen J.G., Waage A., Sundan A., Borset M. A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin. Cancer Res. 10:2004;6686-6694
24. Hurt E.M., Wiestner A., Rosenwald A., Shaffer A.L., Campo E., Grogan T., Bergsagel P.L., Kuehl W.M., Staudt L.M. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 5:2004;191-199
25. Hussein M.A., Saleh M., Ravandi F., Mason J., Rifkin R.M., Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 125:2004;470-476
26. Kwak L.W., Neelapu S.S., Bishop M.R. Adoptive immunotherapy with antigen-specific T cells in myeloma. A model of tumor-specific donor lymphocyte infusion Semin. Oncol. 31:2004;37-46
27. Kyle R.A., Therneau T.M., Rajkumar S.V., Offord J.R., Larson D.R., Plevak M.F., Melton L.J. 3rd. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346:2002;564-569
28. Landowski T.H., Olashaw N.E., Agrawal D., Dalton W.S. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells. Oncogene. 22:2003;2417-2421
29. Lee A.H., Iwakoshi N.N., Anderson K.C., Glimcher L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. USA. 100:2003;9946-9951
30. Lin B., Podar K., Gupta D., Tai Y.T., Li S., Weller E., Hideshima T., Lentzsch S., Davies F., Li C., et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 62:2002;5019-5026
31. Maxwell C.A., Rasmussen E., Zhan F., Keats J.J., Adamia S., Strachan E., Crainie M., Walker R., Belch A.R., Pilarski L.M., et al. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood. 104:2004;1151-1158
32. McCafferty-Grad J., Bahlis N.J., Krett N., Aguilar T.M., Reis I., Lee K.P., Boise L.H. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol. Cancer Ther. 2:2003;1155-1164
33. Mitsiades C.S., Mitsiades N., Poulaki V., Fanourakis G., Hideshima T., Chauhan D., Munshi N.C., Anderson K.C. Hsp90 inhibitors prolong survival in a SCID/NOD mice model of diffuse multiple myeloma. Therapeutic implications Blood. 100:2002;106a. a
34. Mitsiades C.S., Mitsiades N., Poulaki V., Schlossman R., Akiyama M., Chauhan D., Hideshima T., Treon S.P., Munshi N.C., Richardson P.G., Anderson K.C. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells. Therapeutic implications Oncogene. 21:2002;5673-5683. b
35. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M., Libermann T.A., Treon S.P., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA. 99:2002;14374-14379. c
36. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., Munshi N.C., Treon S.P., Anderson K.C. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells. Therapeutic implications Blood. 99:2002;4525-4530. d
37. Mitsiades C.S., Mitsiades N., McMullan C.J., Poulaki V., Hideshima T., Chauhan D., Munshi N.C., Joseph M., Libermann T.A., Anderson K.C. Molecular profiles of sensitivity or resistance of multiple myeloma (MM) cells to conventional and novel anti-myeloma agents. Clinical implications for rationale design of strategies to overcome drug-resistance in MM Blood. 102:2003;659. a
38. Mitsiades C.S., Mitsiades N.S., Bronson R.T., Chauhan D., Munshi N., Treon S.P., Maxwell C.A., Pilarski L., Hideshima T., Hoffman R.M., Anderson K.C. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model. Biologic and clinical implications Cancer Res. 63:2003;6689-6696. b
39. Mitsiades N., Mitsiades C.S., Richardson P.G., McMullan C., Poulaki V., Fanourakis G., Schlossman R., Chauhan D., Munshi N.C., Hideshima T., et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 101:2003;4055-4062. c
40. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.T., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents. Therapeutic applications Blood. 101:2003;2377-2380. d
41. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Akiyama M., Hideshima T., Chauhan D., Joseph M., Libermann T.A., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 5:2004;221-230. a
42. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., Akiyama M., Chauhan D., Munshi N., Gu X., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma. Biological and clinical implications Proc. Natl. Acad. Sci. USA. 101:2004;540-545. b
43. Moreau P., Facon T., Leleu X., Morineau N., Huyghe P., Harousseau J.L., Bataille R., Avet-Loiseau H. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 100:2002;1579-1583
44. Mori Y., Shimizu N., Dallas M., Niewolna M., Story B., Williams P.J., Mundy G.R., Yoneda T. Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood. 104:2004;2149-2154
45. Nefedova Y., Cheng P., Alsina M., Dalton W.S., Gabrilovich D.I. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 103:2004;3503-3510
46. Orlowski R.Z. Bortezomib and its role in the management of patients with multiple myeloma. Expert Rev. Anticancer Ther. 4:2004;171-179
47. Rajkumar S.V., Hayman S., Gertz M.A., Dispenzieri A., Lacy M.Q., Greipp P.R., Geyer S., Iturria N., Fonseca R., Lust J.A., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. 20:2002;4319-4323
48. Rasillo A., Tabernero M.D., Sanchez M.L., Perez de Andres M., Martin Ayuso M., Hernandez J., Moro M.J., Fernandez-Calvo J., Sayagues J.M., Bortoluci A., et al. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. Cancer. 97:2003;601-609
49. Richardson P.G., Schlossman R.L., Weller E., Hideshima T., Mitsiades C., Davies F., LeBlanc R., Catley L.P., Doss D., Kelly K., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 100:2002;3063-3067
50. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348:2003;2609-2617
51. Roux S., Meignin V., Quillard J., Meduri G., Guiochon-Mantel A., Fermand J.P., Milgrom E., Mariette X. RANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma. Br. J. Haematol. 117:2002;86-92
52. Shammas M.A., Shmookler Reis R.J., Li C., Koley H., Hurley L.H., Anderson K.C., Munshi N.C. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin. Cancer Res. 10:2004;770-776
53. Shaughnessy J. Jr., Tian E., Sawyer J., McCoy J., Tricot G., Jacobson J., Anaissie E., Zangari M., Fassas A., Muwalla F., et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma. Early results of total therapy II Br. J. Haematol. 120:2003;44-52
54. Shi Y., Gera J., Hu L., Hsu J.H., Bookstein R., Li W., Lichtenstein A. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 62:2002;5027-5034
55. Shou Y., Martelli M.L., Gabrea A., Qi Y., Brents L.A., Roschke A., Dewald G., Kirsch I.R., Bergsagel P.L., Kuehl W.M. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl. Acad. Sci. USA. 97:2000;228-233
56. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341:1999;1565-1571
57. Sordillo E.M., Pearse R.N. Rank-fc. A therapeutic antagonist for rank-l in myeloma Cancer. 97:2003;802-812
58. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., Shaughnessy J.D. Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349:2003;2483-2494
59. Urashima M., Chen B.P., Chen S., Pinkus G.S., Bronson R.T., Dedera D.A., Hoshi Y., Teoh G., Ogata A., Treon S.P., et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 90:1997;754-765
60. Vanderkerken K., De Leenheer E., Shipman C., Asosingh K., Willems A., Van Camp B., Croucher P. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 63:2003;287-289
61. Weber D., Rankin K., Gavino M., Delasalle K., Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 21:2003;16-19
62. Yaccoby S., Barlogie B., Epstein J. Primary myeloma cells growing in SCID-hu mice. A model for studying the biology and treatment of myeloma and its manifestations Blood. 92:1998;2908-2913
63. Zhan F., Hardin J., Kordsmeier B., Bumm K., Zheng M., Tian E., Sanderson R., Yang Y., Wilson C., Zangari M., et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 99:2002;1745-1757
64. Zhan F., Tian E., Bumm K., Smith R., Barlogie B., Shaughnessy J. Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood. 101:2003;1128-1140